{"entity":{"type":"insider","cik":"0001725722","url":"/insider/0001725722","json_url":"/insider/0001725722.json","name":"AH Equity Partners Bio II, L.L.C.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":3,"n_filings":2,"first":"2026-06-04","last":"2026-07-29","span_basis":"filed_date"},"name_variants":[{"name":"AH Equity Partners Bio II, L.L.C.","source":"filing","n_filings":2,"first_seen":"2026-06-04","last_seen":"2026-07-29"}],"transactions":[{"id":6064495,"accession":"0001231919-26-000813","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-26-000813","line_url":"/filing/0001231919-26-000813#line-3","is_derivative":false,"issuer_cik":"0001160077","issuer_name":"Scribe Therapeutics, Inc.","issuer_ticker":"SCTX","issuer_name_source":null,"issuer_url":"/issuer/0001160077","owner_cik":null,"owner_name":"AH Bio Fund III, L.P.; AH Equity Partners Bio III, L.L.C.; HOROWITZ BENJAMIN A; Andreessen Marc L; AH Equity Partners Bio II, L.L.C.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":333333.0,"shares_display":"333,333","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":4999995.0,"total_display":"4,999,995.00","shares_owned_after":2385075.0,"shares_owned_after_display":"2,385,075","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-27","filed_date":"2026-07-29","scope":"insider"},{"id":5985247,"accession":"0001231919-26-000599","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000599","line_url":"/filing/0001231919-26-000599#line-2","is_derivative":false,"issuer_cik":"0001160077","issuer_name":"Nautilus Biotechnology, Inc.","issuer_ticker":"NAUT","issuer_name_source":null,"issuer_url":"/issuer/0001160077","owner_cik":null,"owner_name":"Andreessen Horowitz LSV Fund II, L.P.; AH Bio Fund II, L.P.; AH Equity Partners LSV II, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN A","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4615974.0,"shares_display":"4,615,974","price_per_share":2.35,"price_display":"2.35","price_state":"stated","total_value":10847538.9,"total_display":"10,847,538.90","shares_owned_after":11682032.0,"shares_owned_after_display":"11,682,032","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-02","filed_date":"2026-06-04","scope":"insider"},{"id":5985243,"accession":"0001231919-26-000599","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000599","line_url":"/filing/0001231919-26-000599#line-1","is_derivative":false,"issuer_cik":"0001160077","issuer_name":"Nautilus Biotechnology, Inc.","issuer_ticker":"NAUT","issuer_name_source":null,"issuer_url":"/issuer/0001160077","owner_cik":null,"owner_name":"Andreessen Horowitz LSV Fund II, L.P.; AH Bio Fund II, L.P.; AH Equity Partners LSV II, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN A","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":384026.0,"shares_display":"384,026","price_per_share":2.35,"price_display":"2.35","price_state":"stated","total_value":902461.1,"total_display":"902,461.10","shares_owned_after":971885.0,"shares_owned_after_display":"971,885","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-02","filed_date":"2026-06-04","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001853921","name":"Scribe Therapeutics, Inc.","url":"/issuer/0001853921","role":"Ten percent owner","n_filings":1,"first_seen":"2026-07-29","last_seen":"2026-07-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001808805","name":"Nautilus Biotechnology, Inc.","url":"/issuer/0001808805","role":"Ten percent owner","n_filings":1,"first_seen":"2026-06-04","last_seen":"2026-06-04"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001725722","retrieved_at":"2026-08-20T21:33:25+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-19","last_ingest":"2026-08-20T05:22:56.381658+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}